share_log

Baird Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $9

Baird Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $9

Baird维持对maravai lifesciences的跑赢市场评级,将目标价格下调至9美元
Benzinga ·  2024/11/08 20:28  · 评级/大行评级

Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and lowers the price target from $10 to $9.

贝尔德分析师凯瑟琳·舒尔特维持Maravai LifeSciences(纳斯达克股票代码:MRVI)的跑赢大盘,并将目标股价从10美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发